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Abstract: Although microsatellite instability-high (MSI-H) colorectal
cancers (CRCs) have been shown to exhibit a distinct phenotype, the
clinical value of MSI-low (MSI-L) in CRC remains unclear. We
designed this study to examine the clinicopathologic characteristics
and oncologic implications associated with MSI-L CRCs.
We retrospectively reviewed data of CRC patients from 3 tertiary
referral hospitals in Korea, who underwent surgical resection between
January 2003 and December 2009 and had available MSI testing results.
MSI testing was performed using the pentaplex Bethesda panel. Clin-
icopathologic features and oncologic outcomes were compared between
MSI-L and microsatellite stable (MSS) CRCs; prognostic factors for
survival were also examined.
Of the 3019 patients reviewed, 2621 (86.8%) were MSS, and 200
(6.6%)wereMSI-L; the remaining 198 (6.6%)wereMSI-H.MSI-L and
MSS CRCs were comparable in terms of their clinicopathologic
features, with the exception of proximal tumor location (MSI-L
30.0% vs MSS 22.1%, P¼ 0.024) and tumor size (MSI-L
5.2 2.6 cm vs MSS 4.6 2.1 cm, P¼ 0.001). No differences were
detected in either 3-year disease-free survival (MSI-L 87.2% vs MSS
82.6%, P¼ 0.121) or 5-year overall survival (OS) (MSI-L 74.2% vs
MSS 78.3%, P¼ 0.131) by univariable analysis. However, MSI-L wasKyu Kim, MD, Ph Lee, MD, PhD,
Sung-Bum Kang, MD, PhD
MSI-L may be an independent prognostic factor for OS in sporadic
CRCs despite their clinicopathologic similarity to MSS. Further
studies investigating the significance of MSI-L in the genesis and
prognosis of CRCs are needed.
(Medicine 94(50):e2260)
Abbreviations: AJCC = American Joint Committee on Cancer,
ASA = American Society of Anesthesiologists, CEA =
carcinoembryonic antigen, CI = confidence interval, CRC =
colorectal cancer, DFS = disease-free survival, EMAST = elevated
microsatellite alterations at selected tetranucleotide repeats, HNPCC
= hereditary nonpolyposis colorectal cancer, HR = hazard ratio, LOH
= loss of heterozygosity, m/d = moderately differentiated, MMR =
mismatch repair, MSI = microsatellite instability, MSI-H =
microsatellite instability-high, MSI-L = microsatellite instability-
low, MSS = microsatellite stable, NCCN = National Comprehensive
Cancer Network, NCI = National Cancer Institute, OS = overall
survival, p/d = poorly differentiated, PCR = polymerase chain
reaction, SRC = signet ring cell, w/d = well differentiated.
INTRODUCTION
M icrosatellite instability (MSI) is defined as a change inlength of tandemly repeated DNA sequences, caused by a
failure of the DNA mismatch repair (MMR) system to correct
for such errors during DNA replication.1,2 MSI, the hallmark of
hereditary nonpolyposis colorectal cancer (HNPCC), is recog-
nized as one of the major carcinogenetic pathways of colorectal
cancer (CRC) and is detected in 15% of sporadic colorectal
cancers.3,4 CRCs can be classified into 3 groups according to the
MSI status: MSI-high (MSI-H), which exhibit  30 to 40%
microsatellite marker instability, MSI-Low (MSI-L), which
exhibit instability at< 30 to 40% of loci, and microsatellite
stable (MSS), which exhibit no unstable markers.1
The primary goal of MSI testing is to detect cases of
HNPCC, as well as sporadic CRCs developed through the
replication error pathway. However, because CRCs with
MSI-H display distinctive clinical features including proximal
tumor location, poorly differentiated or mucinous histology,
large size, lymphocytic infiltration, favorable prognosis, and
decreased chemo-responsiveness,4 MSI testing is also used as a
prognostic marker of disease. In contrast to the strong diag-
nostic value associated with MSI-H tumors, the biologic sig-
nificance of MSI-L CRCs remains unclear. MSI-L CRCs have
often been regarded as indistinct from that of MSS CRCs,
making it uncertain whether or not MSI-L CRCs form a
clinically unique subgroup.1,2,5,6 Some studies have reportedgic features associated with MSI-L
ers observed no significant differences
SS CRCs.11–13 In terms of oncologic
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significance, only a small number of studies examining MSI-L
tumors have been published, with conflicting results.9,10,12–15
To address these apparent inconsistencies, we conducted
an investigation into the clinicopathologic characteristics and
oncologic implications of sporadic CRCs with MSI-L.
METHODS
Hospital Setting and Study Population
Following review of a prospective database, we included
patients subjected to surgery for sporadic CRC and those with
available MSI results. All patients underwent radical surgery
between January 2003 and December 2009 at 1 of 3 tertiary
referral hospitals (Seoul National University Bundang Hospital,
Severance Hospital, and Samsung Medical Center), which were
1300 to 2500-bed teaching hospitals in Seoul, Korea. The study
period was not the same among the 3 institutions, as routineMSI
testing with 5 microsatellite markers (BAT-25, BAT-26,
D2S123, D5S346, and D17S250) was implemented at different
points of time: 2007 in Seoul National University Bundang
Hospital, 2003 in Severance Hospital, and 2006 in Samsung
Medical Center. However, for analyzing long-term oncologic
outcomes, we enrolled patients who underwent surgery before
2009. Patients with recurrent CRC, familial adenomatous poly-
posis, HNPCC, or inflammatory bowel disease were excluded.
This study was approved by the appropriate Institutional
Review Board at each institution.
The basic principles of radical surgery and neoadjuvant/
adjuvant therapy were similar at the 3 institutions. For clinical
T3–4 or N1–2 mid-to-low rectal cancers, neoadjuvant chemor-
adiation was delivered (45.0–50.4 Gy plus 5-fluorouracil/leu-
covorin), and radical surgery was performed 6 to 8 weeks after
completion of neoadjuvant therapy. All patients underwent
standard colectomy or proctectomy and regional lymphadenect-
omy according to tumor location, as described in our previous
studies.16,17 Postoperative adjuvant treatment was determined
by the attending physician based on the pathologic stage and the
general condition of the patient. For patients with stage II CRC
with high-risk features for systemic recurrence, or stage III
CRC, 5-fluorouracil-based postoperative adjuvant treatment
was recommended in accordance with National Comprehensive
Cancer Network (NCCN) guidelines.18,19 For patients who
received neoadjuvant chemoradiation, postoperative adjuvant
chemotherapy was recommended for all patients irrespective of
surgical pathology results, in accordance with NCCN guide-
lines.19 For patients with metastatic disease, cetuximab or
bevacizumab was considered. All cases were restaged retro-
spectively according to the 7th edition of the American Joint
Committee on Cancer (AJCC) TNM staging system.
Patients were monitored at regular intervals, as described
previously.17 The detailed follow-up schedule differed slightly
among the institutions, although all were based on the NCCN
guidelines.18,19Disease-free survival (DFS)was determined from
the date of surgery to the date of recurrence or death, with patients
surviving to at least December 2014 and those lost to follow-up
being censored. Overall survival (OS) was defined as the time
from the date of surgery to the date of death from any cause with
censoring as above. Recurrence was diagnosed via radiological
detection of size-increased lesions or histological confirmation.
Lee et alMSI Analysis
MSI testing was performed on specimens after surgical
resection. DNA was extracted from paraffin-embedded tumor
2 | www.md-journal.comand surrounding normal tissues for each patient. Diagnoses
were confirmed via microscopic examination, with each area
identified on a reference H&E-stained slide, and microdissected
using a scalpel to ascertain the presence of adequate neoplastic
tissue. Five microsatellite markers (BAT-25, BAT-26, D2S123,
D5S346, and D17S250) were used to determine microsatellite
status; markers were selected based upon the recommendations
of a National Cancer Institute (NCI) workshop on MSI.1 Poly-
merase chain reaction (PCR) analyses were performed as
described previously,20 and the shift of PCR products from
tumor DNAwas compared to that of DNA from normal colonic
mucosa. Tumors with at least 2 of the 5 microsatellite markers
displaying shifted alleles were classified as MSI-H, whereas
tumors with only 1 marker exhibiting a shifted allele were
classified as MSI-L. Samples in which all microsatellite mar-
kers displayed identical patterns in tumor and normal tissues
were classified as MSS.
Statistical Analyses
Categorical variables were compared using the x2 or Fish-
er’s exact test; continuous variables were compared using
Student’s t test. Because MSI-H tumors are widely known to
have better prognosis, we excluded MSI-H tumors in survival
analyses to compare the oncologic outcome betweenMSI-L and
MSS CRCs exclusively. Survival rates were estimated and
compared using the Kaplan–Meier method and log-rank test.
Cox regression was utilized for the multivariable survival
analysis, and all variables with P< 0.15 on Kaplan–Meier
survival analysis were entered into the multivariable pro-
portional hazards model. The assumption of proportional
hazards was verified by examination of log cumulative hazard
plots for parallelism. The predictive discrimination of each
prognostic model was examined by calculating Harrell’s con-
cordance index (C-index). All results were considered signifi-
cant at P< 0.05. Statistical analyses were carried out using
SPSS software version 21.0 (IBM Inc., Armonk, NY).
RESULTS
Of the 3019 sporadic CRC patients identified in our
review, 200 (6.6%) had MSI-L CRCs, 198 (6.6%) had MSI-
H CRCs, and the remaining 2621 (86.8%) had MSS CRCs. The
clinicopathologic characteristics of each group are shown in
Table 1. MSI-H tumors were associated with young age,
proximal tumor location, large tumor size, poor differentiation,
and N0 and M0 stages. The majority of features associated with
oncologic outcome, including tumor stage, were similar
between MSI-L and MSS; however, some differences were
observed. A statistically significant difference in tumor location
was observed between MSL-L and MSS tumors, with 30.0% of
MSL-L tumors located in the right colon, compared to only
22.1% for MSS (P¼ 0.024). MSI-L tumors were also larger in
their longest diameter (mean 5.2 cm) relative to MSS tumors
(mean 4.6 cm; P¼ 0.001).
The median follow-up time for all patients was 55 months
(range 0–129), with 3-year DFS seen in 83.6% of patients, and a
5-year OS of 78.9%. Kaplan–Meier survival analysis showed
that preoperative carcinoembryonic antigen, tumor size, TNM
stage, lymphatic, venous, perineural invasion, and tumor differ-
entiation were associated with both DFS and OS (Table 2).
Rectal cancer was associated with shorter DFS times, whereas
Medicine  Volume 94, Number 50, December 2015patient age and American Society of Anesthesiologists (ASA)
score were associated only with OS. MSI-H tumors showed
better DFS (P¼ 0.004) and OS (P< 0.001) compared to MSS
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Correlation Between Microsatellite Status and Clinicopathologic Variables
Characteristics MSS (n¼ 2621) MSI-H (n¼ 198) P MSI-L (n¼ 200) P
Sex Male 1595 (60.9%) 107 (54.0%) 0.059 112 (56.0%) 0.176
Female 1026 (39.1%) 91 (46.0%) 88 (44.0%)
Age (yr) 61.0 11.4 58.2 13.9 0.006 62.3 11.3 0.120
ASA score 1,2 2415 (93.9%) 184 (95.8%) 0.274 173 (92.0%) 0.305
3,4 157 (6.1%) 8 (4.2%) 15 (8.0%)
Location Right colon 579 (22.1%) 113 (57.1%) <0.001 60 (30.0%) 0.024
Left colon 870 (33.2%) 48 (24.2%) 54 (27.0%)
Rectum 1172 (44.7%) 37 (18.7%) 86 (43.0%)
Preop CEA < 5 1800 (70.5%) 163 (84.9%) <0.001 130 (66.3%) 0.221
(ng/mL)  5 754 (29.5%) 29 (15.1%) 66 (33.7%)
Size (cm) 4.6 2.1 6.0 2.7 <0.001 5.2 2.6 0.001
T stage 0 21 (0.8%) 1 (0.5%) 0.624 2 (1.0%) 0.576
1 175 (6.7%) 11 (5.6%) 10 (5.0%)
2 345 (13.2%) 24 (12.1%) 25 (12.5%)
3 1756 (67.0%) 143 (72.2%) 144 (72.0%)
4 324 (12.4%) 19 (9.6%) 19 (9.5%)
N stage 0 1301 (49.7%) 142 (71.7%) <0.001 105 (52.5%) 0.651
1 766 (29.3%) 41 (20.7%) 58 (29.0%)
2 550 (21.0%) 15 (7.6%) 37 (18.5%)
M stage 0 2234 (85.2%) 186 (93.9%) 0.001 173 (86.5%) 0.626
1 387 (14.8%) 12 (6.1%) 27 (13.5%)
TNM stage 0 19 (0.7%) 1 (0.5%) <0.001 2 (1.0%) 0.717
I 405 (15.5%) 30 (15.2%) 26 (13.0%)
II 812 (31.0%) 106 (53.5%) 70 (35.0%)
III 998 (38.1%) 49 (24.7%) 75 (37.5%)
IV 387 (14.8%) 12 (6.1%) 27 (13.5%)
Lymphatic Negative 1764 (68.0%) 157 (80.5%) <0.001 143 (71.5%) 0.306
invasion Positive 830 (32.0%) 38 (19.5%) 57 (28.5%)
Venous Negative 2003 (77.2%) 169 (86.7%) 0.002 159 (79.5%) 0.457
invasion Positive 591 (22.8%) 26 (13.3%) 41 (20.5%)
Perineural Negative 2303 (88.8%) 187 (95.9%) 0.002 173 (86.5%) 0.328
invasion Positive 291 (11.2%) 8 (4.1%) 27 (13.5%)
Differentiation w/d, m/d 2462 (94.5%) 167 (85.2%) <0.001 183 (91.5%) 0.077
p/d, SRC, mucinous 143 (5.5%) 29 (14.8%) 17 (8.5%)
Adjuvant Not performed 638 (25.2%) 52 (26.8%) 0.613 57 (29.1%) 0.225
chemotherapy Performed 1897 (74.8%) 142 (73.2%) 139 (70.9%)
ASA¼American Society of Anesthesiologists, CEA¼ carcinoembryonic antigen, m/d¼moderately differentiated, MSI-H¼microsatellite
instability-high, MSI-L¼microsatellite instability-low, MSS¼ indicates microsatellite stable, p/d¼ poorly differentiated, SRC¼ signet ring cell,
TNM¼ tumor-node-metastasis, w/d¼well differentiated.
Medicine  Volume 94, Number 50, December 2015 MSI-L and Survival in Colorectal Cancertumors (Fig. 1), but MSI-L was not significantly associated with
DFS (P¼ 0.121) or OS (P¼ 0.131) by univariable analysis
(Fig. 1) (Table 2). However, after adjusting for confounders
via multivariable Cox regression, MSI-L was associated with
poorer OS (hazard ratio [HR]¼ 1.354, 95% confidence interval
[CI] 1.011–1.815, P¼ 0.042), as well as other factors (Table 3),
although it was not an independent prognostic factor for DFS
(HR¼ 0.704, 95% CI 0.462–1.074, P¼ 0.104). The C-index of
each model was 0.676 for DFS and 0.805 for OS. The prognostic
model for OS that included MSI had higher C-index (0.805)
than the model without MSI (0.804).
Figure 2 shows the distribution of unstable microsatellite
markers in MSI-L CRCs. The majority of the 200 MSI-L
Compared to MSS.tumors (97.0%) showed instability at dinucleotide repeats
(D5S346 13.5% [27/200], D17S250 34.5% [69/200],
D2S123 49.0% [98/200]), compared with only 3.0% which
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.displayed instability at a mononucleotide repeat (BAT26 1.0%
[2/200], BAT25 2.0% [4/200]).
DISCUSSION
The analyses presented here constitute the largest study to
date examining the clinicopathologic features and oncologic
outcomes associated with MSI-L CRC. In terms of clinico-
pathologic features, sporadic CRCs with MSI-L were broadly
similar to those with MSS, with the only exceptions being that
of tumor location and tumor size. However, among oncologic
outcomes, MSI-L was shown to be an independent predictor of
lower OS.MSI-H CRCs have been reported to demonstrate more
frequent association with proximal location, poorly differen-
tiated or mucinous histology, large size, favorable stage, and
www.md-journal.com | 3
TABLE 2. Univariable Analysis of the Prognostic Factors for 3-Year Disease-Free Survival (3Y DFS) and 5-Year Overall Survival
(5Y OS)
No. 3Y DFS (%) P No. 5Y OS (%) P
Sex Male 1466 82.6 0.581 1707 77.5 0.490
Female 941 83.5 1114 78.8
Age (yr) < 70 1818 83.3 0.153 2141 81.1 < 0.001
 70 589 81.7 680 67.4
ASA score 1, 2 2205 83.2 0.158 2588 78.6 0.002
3, 4 149 79.7 172 68.7
Location Colon 1305 85.6 <0.001 1563 77.8 0.447
Rectum 1102 79.8 1258 78.3
Preoperative < 5 1772 86.3 <0.001 1930 84.3 < 0.001
CEA (ng/mL)  5 576 72.8 820 63.1
Tumor size (cm) < 5 1427 84.6 0.004 1578 82.0 < 0.001
 5 965 80.2 1226 72.5
T stage 0, 1, 2 568 94.3 <0.001 578 94.1 < 0.001
3, 4 1839 79.4 2243 73.8
N stage 0 1330 90.9 <0.001 1406 89.3 < 0.001
1, 2 1073 73.0 1411 66.7
M stage 0 2407 86.2 < 0.001
1 414 29.7
Lymphatic Negative 1722 86.9 <0.001 1907 84.2 < 0.001
invasion Positive 660 71.9 887 63.9
Venous Negative 1925 85.8 <0.001 2162 82.8 < 0.001
invasion Positive 457 70.0 632 61.0
Perineural Negative 2165 84.3 <0.001 2476 79.7 < 0.001
invasion Positive 217 66.8 318 62.4
Differentiation w/d, m/d 2277 83.3 0.003 2645 79.0 < 0.001
p/d, SRC, mucinous 114 73.4 160 58.5
Adjuvant Not performed 624 87.5 0.003 695 79.4 0.928
chemotherapy Performed 1729 81.4 2036 78.7
Microsatellite MSS 2234 82.6 0.121 2621 78.3 0.131
status MSI-L 173 87.2 200 74.2
ASA¼American Society of Anesthesiologists, CEA¼ carcinoembryonic antigen, DFS¼ indicates disease-free survival, m/d¼moderately
differentiated, MSI-L¼microsatellite instability-low, MSS¼microsatellite stable, OS¼ overall survival, p/d¼ poorly differentiated, SRC¼ signet
signet ring cell, TNM¼ tumor-node-metastasis, w/d¼well differentiated.
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However, among published studies, comparisons between
MSI-L and MSS CRCs remain controversial. Several studies
examining CRCs with MSI-L were able to identify clinico-
pathologic features distinct from those of MSS;7–10 however,
these results could not been replicated in all studies.11–13 This
inherent lack of reproducibility between studies raises a funda-
mental question as to whether MSI-L should be regarded as a
distinct genetic subgroup.5,6 It is undeniable that some portion
of MSI-L is misdiagnosed due to technical factors including
PCR amplification errors, different microsatellite markers, and
cut-off levels.21–24 Alternatively, MSI-L may also occur as a
result of random mutational events during neoplastic cell
evolution.24 However, these hypotheses are not sufficient to
explain the specificity of MSI-L tumors.24 Several lines of
molecular evidence have been presented to suggest that MSI-
L forms a biologically discrete subgroup,11,24–26 including
increased frequency of KRAS mutation, lower frequency of
5q loss of heterozygosity (LOH), distinct gene expression
4 | www.md-journal.comprofiles in cDNA microarrays, and others. Here, we showed
that patients with MSI-L tumors had worse overall prognosis
relative to those with MSS tumors despite broadly similar
clinicopathologic features, consistent with the notion of MSI-
L CRCs as a distinct biological entity. Future investigations
using whole genome sequencing may be necessary to determine
the genetic significance of MSI-L, similar to what was done for
MSI-H tumors.27
Beyond clinical features, a number of studies have
examined the impact of MSI-L on oncologic out-
comes,9,10,12–15 although the results have been inconsistent
(Table 4). Some studies described poorer survival in patients
with MSI-L tumors,12–15 whereas others failed to observe any
significant differences9 or favorable oncologic outcomes10 as
compared to patients with MSS tumors. This apparent incon-
sistency between studies may be due to differences in study
design, as each study used a different surrogate for oncologic
outcome, including OS9,10,12–14, DFS,9 cancer-specific survi-
val,12 and recurrent distant metastasis.15 Furthermore, these
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 1. Kaplan–Meier survival curve depicting oncologic out-
comes of sporadic CRC patients according to microsatellite status
(MSI). (A) Disease-free survival. (B) Overall survival. CRC¼ color-
colorectal cancer, MSI¼microsatellite instability.
Medicine  Volume 94, Number 50, December 2015studies have a number of weaknesses, such as a small number of
MSI-L tumors,9,10,12–15 inclusion of MSI-H tumors when com-
paring survival outcome,10,13 or inclusion only of patients with
stage II or III tumors.12,14,15 All of these differences make it
difficult to draw solid conclusions. The present large multi-
center study identified MSI-L as an independent prognostic
factor for OS, consistent with previous reports of poor OS in
patients with MSI-L tumors.13,14
It is noteworthy that MSI-L was an independent prognostic
factor for OS, but not for DFS, despite the strong association
generally seen between these 2 outcomes. Actually, a previous
study also demonstrated reduced cancer-specific survival but no
difference in overall survival of MSI-L compared with MSS.12
One of the possible reasons is that significant but subtle impact
of MSI-L on survival might bring about this discrepancy
between survival surrogates. In this case, OS is considered
the more definitive end point due to its obvious clinical import-
ance and unambiguous nature,28 whereas DFS is not always an
appropriate surrogate of OS. Although DFS has been shown to
exhibit a strong association with OS in adjuvant colon cancer
studies,29 any statistical association between DFS and OS
would be weakened if survival after recurrence were
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.prolonged.28,30 We are unable to explain why MSI-L was
associated with OS but not DFS; however, in this instance
we think that this lack of correlation does not weaken the
prognostic significance of MSI-L, as the most significant
association was seen with the more important survival endpoint.
Another statistical issue is that the prognostic effect of
MSI-L only emerges when using the multivariable model.
Frequently, a variable that is not significantly associated with
an outcome by univariable analysis can be identified as an
independent risk factor in multivariable analysis after adjusting
for the effects of the other variables. Whereas such an obser-
vation on its own may not be sufficient to prove an association,
we think that the comprehensive nature of this study and the
strong statistical power provided by use of a large, unbiased,
multicenter study population is sufficient to demonstrate MSI-L
as a potential prognostic factor in sporadic CRCs.
Previous studies have presented evidence demonstrating a
distinct genetic pathway underlying the development of MSI-L
tumors. MSI-L phenotype was reported to be strongly associ-
ated with serrated or hyperplastic polyps with an alternative
histological pathway.25,31 Asaka et al32 suggested that MSI-L
have different timing and frequency of the KRAS mutation,
which may influence the oncologic outcome. Some other
studies demonstrated different levels of LOH at 1p32, 8p12–
22, 5q, and 18q, all of which may be associated with prog-
nosis.10,11,25 Low expression of O6-methylguanine DNA meth-
yltransferase due to promoter hypermethylation is associated
with both KRAS and p53 mutation, which may result in poor
survival.10,14 Recently, some authors surmised that hypoxia
associated with loss of MSH3 may be related to the recurrence
of MSI-L tumors.15 Further translational studies are needed to
identify the distinct genetic pathways driving MSI-L oncogen-
esis, which may provide insights into potential adjuvant therapy
responsiveness, along with targeted therapy of MSI-L CRCs.
In the present study, the majority of instability in MSI-L
CRCs was associated with dinucleotide repeats. This obser-
vation is consistent with previous observations of dinucleotide
marker instability in a majority of MSI-L CRCs.12,32 However,
the classification of microsatellite status is, to some degree,
dependent on the markers used for detection.33 Here, we used
the most widely used 5 markers recommended by the NCI,
although other many studies have been performed to improve
the microsatellite panel for the detection of MMR defects.4,34,35
The revised Bethesda guidelines recommended the use of 5
mononucleotide repeats for the detection of MSI-H tumors due
to the high sensitivity of this assay,2,34 and a simplified mono-
nucleotide panel (BAT-25 and BAT-26) is still used for con-
venience. However, using only mononucleotide markers would
miss possible MSI-L tumors, as they are insensitive for detect-
ing MSI-L cancers.24,36 On the other hand, the revised Bethesda
guidelines also recommend that a secondary mononucleotide
repeat, such as BAT40, should be tested if only dinucleotide
repeats are mutated. BAT40, which has been shown to be
mutated in >75% of MSI-H patients,12 was not tested in this
study, raising the possibility that some MSI-H tumors may have
been erroneously classified as MSI-L in this study due to the
panel utilized. A comprehensive microsatellite panel which
includes dinucleotide markers and is sensitive for both MSI-
H and MSI-L tumors is warranted for the accurate diagnosis on
CRC patients.24
Interestingly, MSI-H and MSI-L tumors accounted for
MSI-L and Survival in Colorectal Canceronly 6.6% of all colorectal cancers respectively, which appears
lower than that reported previously from Western countries
(15–25%).20 However, the frequencies of MSI-H and MSI-L
www.md-journal.com | 5
TABLE 3. Multivariable Analysis of the Prognostic Factors for Disease-Free Survival and Overall Survival
Hazard Ratio (95% CI) P
Disease-free survival
Location (rectum vs colon) 1.527 (1.257–1.854) < 0.001
Preoperative CEA ( 5 ng/mL vs < 5 ng/mL) 1.591 (1.298–1.950) < 0.001
Tumor size ( 5 cm vs < 5 cm) 0.984 (0.806–1.200) 0.870
T stage (3, 4 vs 0, 1, 2) 2.145 (1.509–3.048) < 0.001
N stage (1, 2 vs 0) 2.196 (1.748–2.759) < 0.001
Lymphatic invasion (positive vs negative) 1.101 (0.822–1.476) 0.518
Venous invasion (positive vs negative) 1.335 (0.991–1.799) 0.057
Perineural invasion (positive vs negative) 1.494 (1.136–1.967) 0.004
Differentiation (p/d, SRC, mucinous vs w/d, m/d) 1.346 (0.918–1.972) 0.128
Adjuvant chemotherapy (performed vs not performed) 1.035 (0.810–1.322) 0.784
Microsatellite status (MSI-L vs MSS) 0.704 (0.462–1.074) 0.104
Overall survival
Age ( 70 yr vs < 70 yr) 2.101 (1.763–2.505) < 0.001
ASA (3, 4 vs 1, 2) 1.449 (1.063–1.974) 0.019
Preoperative CEA ( 5 ng/mL vs < 5 ng/mL) 1.476 (1.241–1.755) < 0.001
Tumor size ( 5 cm vs < 5cm) 1.030 (0.869–1.222) 0.730
T stage (3, 4 vs 0, 1, 2) 1.967 (1.371–2.823) < 0.001
N stage (1, 2 vs 0) 1.541 (1.253–1.895) < 0.001
M stage (1 vs 0) 5.472 (4.547–6.586) < 0.001
Lymphatic invasion (positive vs negative) 1.420 (1.122–1.798) 0.004
Venous invasion (positive vs negative) 1.204 (0.956–1.517) 0.114
Perineural invasion (positive vs negative) 1.083 (0.866–1.355) 0.484
Differentiation (p/d, SRC, mucinous vs w/d, m/d) 1.534 (1.172–2.010) 0.002
Microsatellite status (MSI-L vs MSS) 1.354 (1.011–1.815) 0.042
Variables with P < 0.15 on univariable survival analysis were entered into each model.
ASA¼American Society of Anesthesiologist, CEA¼ carcinoembryonic antigen, CI¼ indicates confidence interval, m/d¼moderately differ-
entiated, MSI-L¼microsatellite instability-low, MSS¼microsatellite stable, p/d¼ poorly differentiated, SRC¼ signet ring cell, TNM¼ tumor-
node-metastasis, w/d¼well differentiated.
Lee et al Medicine  Volume 94, Number 50, December 2015were not largely different among the 3 institutions (MSI-H,
3.4–7.4%; MSI-L, 4.1–7.2%). In the previous study, we
suggested a possible explanation that ethnic differences in
the molecular characteristics of colorectal carcinogenesis could
FIGURE 2. Distribution of unstablemicrosatellitemarkers inMSI-L
colorectal cancers. The most frequent unstable marker of MSI in
our MSI-L tumors was D2S123 (49%). MSI¼microsatellite
instability, MSI-L¼microsatellite instability-low.
6 | www.md-journal.comaffect the MSI status.20 This large multicenter study confirmed
low frequencies of MSI-H and MSI-L in Korean patients with
colorectal cancer.
The present study has several limitations. First, as
described above, the classification of microsatellite status is
limited by the number of markers used, which may have
resulted in misclassifications. Second, we did not review indi-
vidual chemotherapy regimens in detail. Although the pro-
portion of adjuvant chemotherapy was not different between
MSI-L and MSS groups, detailed regimens, including target
therapy, could have affected oncologic outcomes. Lastly,
because of the retrospective study design, we could not evaluate
mutations of BRAF and KRAS. Nevertheless, the great strength
of our study is that we used large, consecutive, and multicenter
study populations to reduced selection bias, and showed MSI-L
to be a poor prognostic factor for all stage sporadic CRCs.
Further translational research should focus on the genetic
mechanisms underlying MSI-L tumorigenesis using clinically
discrete groups in terms of oncologic outcome. These efforts
would be the most likely to bring about a positive impact on the
diagnosis and management of CRCs.
In conclusion, we identified MSI-L as an independent
prognostic factor for OS in sporadic CRCs despite clinicopatho-
logic similarities between MSI-L and MSS tumors. Further
clinical and translational studies are needed to investigate the
significance of MSI-L in the genesis and prognosis of CRCs.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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